Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02142803 · OUTCOME

Number of Patients That Discontinue Study Drugs Due to Treatment Related Toxicity

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 2 years

What was measured

Number of patients that discontinue study drugs due to treatment related toxicity; percentage will be summarized.

Groups in this outcome

Dose Level 1 - 3 mg MLN0128 Daily

Stage 1 - Dose Level 1 participants: * 3 mg MLN0128 daily * \+ 10 mg/kg bevacizumab every 2 weeks

Dose Level 2 - 4 mg MLN0128 Daily

Stage 1 - Dose Level 2 participants: * 4 mg MLN0128 daily * \+ 10 mg/kg bevacizumab every 2 weeks

Dose Level 3 - 5 mg MLN0128 Daily

Inclusive of both Stage 1 - Dose Level 3 participants and Stage 2 participants treated at the MTD: * 5 mg MLN0128 daily * \+ 10 mg/kg bevacizumab every 2 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Level 1 - 3 mg MLN0128 Daily3
Dose Level 2 - 4 mg MLN0128 Daily3
Dose Level 3 - 5 mg MLN0128 Daily43

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dose Level 1 - 3 mg MLN0128 Daily0Not reportedNot reportedNot reportedNot reported
Dose Level 2 - 4 mg MLN0128 Daily0Not reportedNot reportedNot reportedNot reported
Dose Level 3 - 5 mg MLN0128 Daily10Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        10
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      43
    units
    Participants
description
Number of patients that discontinue study drugs due to treatment related toxicity; percentage will be summarized.
groups
  1. description
    Stage 1 - Dose Level 1 participants: * 3 mg MLN0128 daily * \+ 10 mg/kg bevacizumab every 2 weeks
    id
    OG000
    title
    Dose Level 1 - 3 mg MLN0128 Daily
  2. description
    Stage 1 - Dose Level 2 participants: * 4 mg MLN0128 daily * \+ 10 mg/kg bevacizumab every 2 weeks
    id
    OG001
    title
    Dose Level 2 - 4 mg MLN0128 Daily
  3. description
    Inclusive of both Stage 1 - Dose Level 3 participants and Stage 2 participants treated at the MTD: * 5 mg MLN0128 daily * \+ 10 mg/kg bevacizumab every 2 weeks
    id
    OG002
    title
    Dose Level 3 - 5 mg MLN0128 Daily
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Up to 2 years
title
Number of Patients That Discontinue Study Drugs Due to Treatment Related Toxicity
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice